KR20180114253A - 항바이러스성 화합물의 제조 방법 - Google Patents

항바이러스성 화합물의 제조 방법 Download PDF

Info

Publication number
KR20180114253A
KR20180114253A KR1020187029248A KR20187029248A KR20180114253A KR 20180114253 A KR20180114253 A KR 20180114253A KR 1020187029248 A KR1020187029248 A KR 1020187029248A KR 20187029248 A KR20187029248 A KR 20187029248A KR 20180114253 A KR20180114253 A KR 20180114253A
Authority
KR
South Korea
Prior art keywords
compound
formula
acid
sodium
reaction conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187029248A
Other languages
English (en)
Korean (ko)
Inventor
케빈 엠. 앨런
신지 후지모리
라르즈 브이. 호이만
그레이스 메이 후인
케이티 앤 키튼
크리스토퍼 엠. 레빈스
가나파티 레디 파물라파티
벤자민 제임스 로버츠
케샤브 사르마
마틴 제럴드 테레스크
시앙 왕
스코트 앨런 월켄하우어
Original Assignee
길리애드 파마셋 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 길리애드 파마셋 엘엘씨 filed Critical 길리애드 파마셋 엘엘씨
Publication of KR20180114253A publication Critical patent/KR20180114253A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)
KR1020187029248A 2014-06-11 2015-06-08 항바이러스성 화합물의 제조 방법 Ceased KR20180114253A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462010813P 2014-06-11 2014-06-11
US62/010,813 2014-06-11
PCT/US2015/034655 WO2015191437A1 (en) 2014-06-11 2015-06-08 Processes for preparing antiviral compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177000461A Division KR101908642B1 (ko) 2014-06-11 2015-06-08 항바이러스성 화합물의 제조 방법

Publications (1)

Publication Number Publication Date
KR20180114253A true KR20180114253A (ko) 2018-10-17

Family

ID=53783899

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187029248A Ceased KR20180114253A (ko) 2014-06-11 2015-06-08 항바이러스성 화합물의 제조 방법
KR1020177000461A Active KR101908642B1 (ko) 2014-06-11 2015-06-08 항바이러스성 화합물의 제조 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177000461A Active KR101908642B1 (ko) 2014-06-11 2015-06-08 항바이러스성 화합물의 제조 방법

Country Status (18)

Country Link
US (5) US9670187B2 (enExample)
EP (1) EP3154984B1 (enExample)
JP (4) JP6295348B2 (enExample)
KR (2) KR20180114253A (enExample)
CN (1) CN106488920A (enExample)
AR (1) AR105050A1 (enExample)
AU (3) AU2015274967B2 (enExample)
BR (1) BR112016028773B1 (enExample)
CA (1) CA2951138C (enExample)
EA (1) EA201692219A1 (enExample)
ES (1) ES2690868T3 (enExample)
IL (1) IL248960A0 (enExample)
MX (1) MX2016016297A (enExample)
NZ (1) NZ726356A (enExample)
PT (1) PT3154984T (enExample)
SG (1) SG11201609828SA (enExample)
TW (2) TW202014413A (enExample)
WO (1) WO2015191437A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2345659A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
JP5905020B2 (ja) 2010-11-17 2016-04-20 ギリアド ファーマセット エルエルシー 抗ウイルス化合物
PT3431477T (pt) 2011-11-16 2020-12-15 Gilead Pharmasset Llc Imidazolilimidazolos condensados como compostos antivirais
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
TW202014413A (zh) * 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
WO2017060820A1 (en) * 2015-10-08 2017-04-13 Mylan Laboratories Limited Process for the preparation of velpatasvir
WO2017112531A1 (en) * 2015-12-21 2017-06-29 Merck Sharp & Dohme Corp. Silane-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
CN105712969B (zh) * 2016-01-27 2018-07-27 杭州科巢生物科技有限公司 维帕他韦中间体的合成方法
CN105732765B (zh) * 2016-02-01 2019-07-26 杭州科巢生物科技有限公司 丙肝药物维帕他韦的新合成方法
CN105732563B (zh) * 2016-03-23 2018-08-28 江苏苏利精细化工股份有限公司 一种合成9-溴-3-(2-溴乙酰基)-10，11-二氢-5H-二苯并[c,g]色烯-8(9h)-酮的新方法
WO2017191546A1 (en) * 2016-05-05 2017-11-09 Laurus Labs Private Ltd. Process for the preparation of intermediates useful in the preparation of hepatitis c virus (hcv) inhibitors
CN109071440A (zh) * 2016-05-13 2018-12-21 日产化学株式会社 2-乙酰基吡啶化合物的制造方法
CN106220639A (zh) * 2016-07-22 2016-12-14 上海众强药业有限公司 一种维帕他韦中间体新晶型
CN107759577B (zh) * 2016-11-30 2020-03-27 上海博志研新药物技术有限公司 Gs5816中间体、制备方法及应用
CN106831737B (zh) * 2017-02-27 2020-03-17 上海众强药业有限公司 维帕他韦及其衍生物的制备
CN107629029A (zh) * 2017-09-19 2018-01-26 安徽省诚联医药科技有限公司 维帕他韦中间体的制备方法
CN107501229A (zh) * 2017-09-27 2017-12-22 上海泓博智源医药股份有限公司 一种维帕他韦中间体的制备方法
CN107987125A (zh) * 2017-11-23 2018-05-04 爱斯特（成都）生物制药股份有限公司 一种缬氨酸衍生物的制备方法
CN108218755A (zh) * 2018-01-18 2018-06-29 上海仁实医药科技有限公司 一种N-Boc-4-氧代-L-脯氨酸叔丁酯的合成工艺
CN110835353B (zh) * 2018-08-15 2022-08-19 上海茂晟康慧科技有限公司 一种艾日布林中间体er804698的合成方法
CN109265431B (zh) * 2018-10-09 2020-05-26 江苏苏利精细化工股份有限公司 3-乙酰基-10，11-二氢-5h-二苯并[c,g]色烯-8（9h）-酮合成工艺
IT201900018488A1 (it) * 2019-10-10 2021-04-10 Dr Schaer S P A Procedimento di preparazione del tris-(3-idrossibutirrato)-gliceril estere
IT201900018491A1 (it) * 2019-10-10 2021-04-10 Dr Schaer S P A Procedimento di purificazione del tris-(3-idrossibutirrato)-gliceril estere
CN111018870B (zh) * 2019-11-29 2021-07-23 南京正济医药研究有限公司 一种维帕他韦中间体的制备方法
CN112275146B (zh) * 2020-09-01 2021-08-20 中国科学院山西煤炭化学研究所 一种经磷酸处理的Tröger`s Base聚合物气体分离膜及其制备方法和应用
CN116462627A (zh) * 2023-04-19 2023-07-21 南京优氟医药科技有限公司 一种3-溴代哌啶-2,6-二酮的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2473056A4 (en) * 2009-09-04 2013-02-13 Glaxosmithkline Llc CHEMICAL COMPOUNDS
UA108211C2 (uk) * 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
EP2503881B1 (en) * 2009-11-25 2015-05-13 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
JP5905020B2 (ja) * 2010-11-17 2016-04-20 ギリアド ファーマセット エルエルシー 抗ウイルス化合物
PT3431477T (pt) * 2011-11-16 2020-12-15 Gilead Pharmasset Llc Imidazolilimidazolos condensados como compostos antivirais
US20150203474A1 (en) * 2012-02-13 2015-07-23 Presidio Pharmaceuticals ,Inc. Solid forms comprising inhibitors of hcv ns5a, compositions thereof, and uses therewith
US20130309196A1 (en) * 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9056860B2 (en) * 2012-06-05 2015-06-16 Gilead Pharmasset Llc Synthesis of antiviral compound
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
TW202014413A (zh) 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法

Also Published As

Publication number Publication date
NZ726356A (en) 2018-06-29
EA201692219A1 (ru) 2017-05-31
BR112016028773A2 (pt) 2017-08-22
TWI679203B (zh) 2019-12-11
US20150361073A1 (en) 2015-12-17
CA2951138A1 (en) 2015-12-17
JP6954959B2 (ja) 2021-10-27
AU2020264335A1 (en) 2020-11-26
JP2019178179A (ja) 2019-10-17
KR101908642B1 (ko) 2018-10-17
EP3154984A1 (en) 2017-04-19
AR105050A1 (es) 2017-09-06
US20200392100A1 (en) 2020-12-17
IL248960A0 (en) 2017-01-31
AU2015274967B2 (en) 2018-04-05
US20190263771A1 (en) 2019-08-29
KR20170015493A (ko) 2017-02-08
US10584109B2 (en) 2020-03-10
US20180179175A1 (en) 2018-06-28
AU2018204886A1 (en) 2018-07-26
AU2015274967A1 (en) 2016-12-01
JP2021178872A (ja) 2021-11-18
TW202014413A (zh) 2020-04-16
AU2020264335B2 (en) 2022-10-27
US9890134B2 (en) 2018-02-13
SG11201609828SA (en) 2016-12-29
AU2018204886B2 (en) 2020-08-06
ES2690868T3 (es) 2018-11-22
MX2016016297A (es) 2017-05-01
PT3154984T (pt) 2018-11-07
BR112016028773B1 (pt) 2023-02-07
US11192875B2 (en) 2021-12-07
EP3154984B1 (en) 2018-08-15
CN106488920A (zh) 2017-03-08
TW201609744A (zh) 2016-03-16
US9670187B2 (en) 2017-06-06
WO2015191437A1 (en) 2015-12-17
JP2017517541A (ja) 2017-06-29
CA2951138C (en) 2019-12-24
JP6295348B2 (ja) 2018-03-14
JP2018052985A (ja) 2018-04-05
US20170283390A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
KR101908642B1 (ko) 항바이러스성 화합물의 제조 방법
EP3752496B1 (en) Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
TWI710547B (zh) 抗病毒化合物之合成
KR20160118359A (ko) 2-(아미노 에틸옥시) 벤조산 유도체의 고리화에 의한 3,4-디히드로-1,4-벤족사제핀-5(2h)-온 유도체의 제조
HK1236198B (en) Processes for preparing antiviral compounds
HK1236198A1 (en) Processes for preparing antiviral compounds
HK1234751A1 (en) Processes for preparing antiviral compounds
HK40098132A (en) Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
HK40043126B (en) Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
HK40043126A (en) Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20181010

Application number text: 1020177000461

Filing date: 20170106

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200602

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200617

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20201124

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210322

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20201124

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20200617

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I